The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma.
 
Andrew Ip
Stock and Other Ownership Interests - Merck (I)
Consulting or Advisory Role - TG Therapeutics
Speakers' Bureau - AstraZeneca
(OPTIONAL) Uncompensated Relationships - COTA; Genomic Testing Cooperative
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Mary E. Warren
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Owen Brady
No Relationships to Disclose
 
Ronglai Shen
No Relationships to Disclose
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Other Relationship - Mirati Therapeutics; Pfizer; Roche/Genentech; Takeda